Welcome to our dedicated page for Brainsway Ltd. SEC filings (Ticker: BWAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BrainsWay Ltd.'s SEC filings document foreign private issuer current reports for a medical technology company focused on noninvasive neurostimulation for mental health disorders. Recent Form 6-K reports furnish press releases and investor materials covering Deep TMS commercialization, FDA-cleared indications, payer reimbursement policies, clinical data, financial results, operating guidance, and strategic investments in provider networks and related neurostimulation assets.
The filings also identify the company as a Form 20-F filer and reference registration statements on Form S-8 and Form F-3. Exhibits disclose capital-allocation activity, customer and reimbursement developments, risk-factor themes in investor materials, and formal updates on the business model built around leasing and selling Deep TMS systems.
Brainsway Ltd. Chief Technology Officer Moiseyev Gilad reported multiple equity transactions. On May 25, 2026, he exercised stock options for 7,500 Ordinary Shares at an exercise price of NIS 11.17 per share, and the company retained 1,902 shares at NIS 44.04 per share to cover the option exercise.
On June 15, 2026, he sold 5,000 Ordinary Shares in an open-market transaction at a sale price of NIS 42.0397 per share, leaving him with 53,098 Ordinary Shares held directly. Footnotes indicate remaining stock options to purchase 13,125 Ordinary Shares vesting in equal quarterly installments until March 5, 2028, alongside additional unvested RSUs that settle in Ordinary Shares over future dates.
BrainsWay Ltd. reported a major expansion of insurance coverage for its SWIFT™ Accelerated Deep TMS™ protocol in the United States. Following several favorable policy changes, including a newly issued policy covering 2 million members in South Carolina, more payers now reimburse this accelerated treatment approach.
With these updates, eight major payers and the U.S. Department of Veterans Affairs now either cover or include policy language supporting accelerated TMS treatment approaches, representing over 57 million covered lives. Management highlights this as evidence of growing adoption of Deep TMS therapies and broader patient access.
The company positions itself as a leader in noninvasive neurostimulation, with its Deep TMS platform cleared by the FDA for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay emphasizes ongoing clinical research and collaboration with providers and policymakers to further expand access to its treatments.
BrainsWay Ltd. filed a Form 6-K highlighting new 12-month durability data for its FDA-cleared SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for Major Depressive Disorder. In a prospective multisite randomized controlled trial, over 80% of patients treated with the SWIFT protocol remained in remission through 12 months based on clinician-rated assessments.
The share of patients with severe functional impairment fell from 85% at baseline to 0% at 12 months, indicating marked improvement in daily functioning, work, and social life. Fewer than 25% of patients needed a medication change or another TMS course during the year. Similar durable benefits were also seen with BrainsWay’s standard once-daily Deep TMS protocol, supporting the long-term durability of the technology for depression treatment.
Brainsway Ltd. Chief Scientist Dr. Roth Yiftach reported open-market sales of a total of 7,000 Ordinary Shares on June 1–2, 2026. The filing notes sale prices between NIS 42.0035 and NIS 43.64 per share. After these transactions, he directly holds 1,072,305 Ordinary Shares, including shares held jointly with his spouse and 5,000 unvested RSUs that vest in stages through March 10, 2030. The Ordinary Shares may also be represented by American Depositary Shares, each currently equal to one Ordinary Share.
Brainsway Ltd. ownership disclosure: an amendment to a Schedule 13G/A reports holdings by MEITAV-related entities as of June 01, 2026. The filing lists 2,532,352 shares and 2,069,247 shares held by affiliated entities, representing 6.31% and 5.16% of ordinary shares, respectively, based on 40,091,644 Ordinary Shares outstanding as of June 01, 2026.
The filing explains these securities are held by various direct or indirect subsidiaries that make independent voting and investment decisions and disclaims formation of any Section 13(d) group. Signatures are provided by Ilan Raviv and Hagai Oren on 06/01/2026.
Brainsway Ltd. director Michal Ety Mitrany Rayten reported open-market sales of a total of 17,980 Ordinary Shares over two days. The shares were sold at prices of NIS 45.5588 and NIS 44.7516 per share. Following these transactions, she holds 12,500 Ordinary Shares, including 6,250 unvested RSUs that vest quarterly until March 5, 2028. The Ordinary Shares may also be held as American Depositary Shares, each currently representing one Ordinary Share.
Brainsway Ltd. director Mitrany Rayten Michal Ety exercised stock options for 27,500 Ordinary Shares and settled related taxes with shares. On May 19–20, 2026, 27,500 options with an exercise price of NIS 15.26 per share were exercised, while 9,520 Ordinary Shares were retained by the company at NIS 44.36 and NIS 43.92 per share to cover the exercise price and tax liabilities.
Following these transactions, the director holds 30,480 Ordinary Shares directly, a figure that includes unvested RSUs for 6,250 shares that vest quarterly until March 5, 2028. The Ordinary Shares may also be represented by American Depositary Shares, each currently equal to one Ordinary Share. The filing reflects routine compensation-related activity rather than open‑market buying or selling.
BrainsWay Ltd. reported a strategic equity investment in Hopemark Health, a mental health clinic platform in the greater Chicago area. BrainsWay will invest $1.5 million initially, with potential for an additional $1.5 million through milestone-based investments, in a minority preferred, annually compounding security with a redemption mechanism.
The partnership aligns with BrainsWay’s strategy of taking minority stakes in North American mental health providers to expand access to its Deep TMS neurostimulation treatments and raise awareness of advanced interventional psychiatry solutions, while allowing BrainsWay to remain focused on advancing its core business and technology.
BrainsWay Ltd. reported strong Q1 2026 growth and profitability while emphasizing its shift to a high-margin recurring revenue model. Q1 2026 revenue rose 35% year over year to about $15.5 million, with net income more than doubling to roughly $2.3 million and Adjusted EBITDA up 117% to about $2.8 million.
The company shipped a record 117 Deep TMS systems in the quarter, expanding its installed base to roughly 1,820 systems and supporting an ARR-focused lease and pay-per-use model. Remaining performance obligations reached about $75 million and cash was $58 million as of March 31, 2026, with no debt.
BrainsWay reiterated full-year 2026 guidance for revenue of $66–68 million, operating income margin of 13–14%, and Adjusted EBITDA of $12–14 million. The company highlighted expanded reimbursement, new clinical indications under development, and minority investments in mental health providers as additional growth drivers.
BrainsWay Ltd. ownership disclosure: Masters Capital Management, LLC and Michael Masters report beneficial ownership of 1,500,000 Ordinary Shares of BrainsWay Ltd., representing 3.8% of the class. The percent is calculated using 39,165,806 Ordinary Shares outstanding as of December 31, 2025.
The filing is an amendment (Schedule 13G/A, Amendment No. 2) and lists shared voting and dispositive power of 1,500,000 shares held directly by Masters Funds. Signatures are by Michael Masters dated 05/13/2026.